These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 33812679)

  • 21. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
    Packer M
    Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity.
    Sano M
    J Cardiol; 2018 May; 71(5):471-476. PubMed ID: 29415819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Bioinformatics Investigation into the Pharmacological Mechanisms of Sodium-Glucose Co-transporter 2 Inhibitors in Diabetes Mellitus and Heart Failure Based on Network Pharmacology.
    Mai Z; Li H; Chen G; Chen E; Liu L; Lun Z; Lai W; Zhou C; Yu S; Liu J; Chen S; Chen J; Liu Y
    Cardiovasc Drugs Ther; 2022 Aug; 36(4):713-726. PubMed ID: 34028657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploration of the clinical benefits of sodium glucose co-transporter 2 inhibitors in diabetic patients with concomitant heart failure.
    Tanaka A; Node K
    Cardiovasc Diabetol; 2018 May; 17(1):74. PubMed ID: 29801492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure.
    Seferović PM; Fragasso G; Petrie M; Mullens W; Ferrari R; Thum T; Bauersachs J; Anker SD; Ray R; Çavuşoğlu Y; Polovina M; Metra M; Ambrosio G; Prasad K; Seferović J; Jhund PS; Dattilo G; Čelutkiene J; Piepoli M; Moura B; Chioncel O; Ben Gal T; Heymans S; Jaarsma T; Hill L; Lopatin Y; Lyon AR; Ponikowski P; Lainščak M; Jankowska E; Mueller C; Cosentino F; Lund LH; Filippatos GS; Ruschitzka F; Coats AJS; Rosano GMC
    Eur J Heart Fail; 2020 Nov; 22(11):1984-1986. PubMed ID: 33068051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors.
    Vaduganathan M; Januzzi JL
    Am J Cardiol; 2019 Dec; 124 Suppl 1():S20-S27. PubMed ID: 31741436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects.
    Palmiero G; Cesaro A; Vetrano E; Pafundi PC; Galiero R; Caturano A; Moscarella E; Gragnano F; Salvatore T; Rinaldi L; Calabrò P; Sasso FC
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors.
    Salvatore T; Galiero R; Caturano A; Rinaldi L; Di Martino A; Albanese G; Di Salvo J; Epifani R; Marfella R; Docimo G; Lettieri M; Sardu C; Sasso FC
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409011
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatments for skeletal muscle abnormalities in heart failure: sodium-glucose transporter 2 and ketone bodies.
    Takada S; Sabe H; Kinugawa S
    Am J Physiol Heart Circ Physiol; 2022 Feb; 322(2):H117-H128. PubMed ID: 34860594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure.
    Bjornstad P; Greasley PJ; Wheeler DC; Chertow GM; Langkilde AM; Heerspink HJL; Van Raalte DH
    J Card Fail; 2021 Dec; 27(12):1447-1455. PubMed ID: 34289398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
    Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
    Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis.
    Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
    Cardiovasc Diabetol; 2022 Feb; 21(1):20. PubMed ID: 35123480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.
    Ferrari F; Martins VM; Scheffel RS; da Silveira AD; Motta MT; Moriguchi EH; Santos RD; Stein R
    Ann Pharmacother; 2021 Oct; 55(10):1267-1275. PubMed ID: 33401940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CaMKII and GLUT1 in heart failure and the role of gliflozins.
    Trum M; Wagner S; Maier LS; Mustroph J
    Biochim Biophys Acta Mol Basis Dis; 2020 Jun; 1866(6):165729. PubMed ID: 32068116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
    Teo YH; Teo YN; Syn NL; Kow CS; Yoong CSY; Tan BYQ; Yeo TC; Lee CH; Lin W; Sia CH
    J Am Heart Assoc; 2021 Feb; 10(5):e019463. PubMed ID: 33625242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure.
    Bhatt DL; Verma S; Braunwald E
    Cell Metab; 2019 Nov; 30(5):847-849. PubMed ID: 31693879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure?
    Voorrips SN; Saucedo-Orozco H; Sánchez-Aguilera PI; De Boer RA; Van der Meer P; Westenbrink BD
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diuretic Action of Sodium-Glucose Cotransporter 2 Inhibitors and Its Importance in the Management of Heart Failure.
    Kimura G
    Circ J; 2016 Oct; 80(11):2277-2281. PubMed ID: 27599528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SGLT2 Inhibition: Changing What Fuels the Heart.
    Lehrke M
    J Am Coll Cardiol; 2019 Apr; 73(15):1945-1947. PubMed ID: 30999997
    [No Abstract]   [Full Text] [Related]  

  • 40. Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design.
    Singh JS; Fathi A; Vickneson K; Mordi I; Mohan M; Houston JG; Pearson ER; Struthers AD; Lang CC
    Cardiovasc Diabetol; 2016 Jul; 15():97. PubMed ID: 27422625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.